Bora Pharmaceuticals acquires biologics CDMO facility

Bora says the acquisition will allow it to rapidly build a presence in the biopharmaceuticals market. 

The acquisition of the CDMO facility, located in Hsinchu Biomedical Science Park, Taiwan, will equip Bora with technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, the establishment of quality control and inspection specifications, as well as cell bank generation. 

Speaking about the news, Bora Vice President Simon Chen said: ‘The addition of the CDMO facilities, equipment and the expertise of the highly qualified team gives Bora Biologics the ability to develop and continue with our clients as they progress to commercialisation.’ 

He noted that the facility contains four 500L bioreactors, all of which have been certified by the EU Qualified Person (QP) and the Taiwan Food and Drug Administration.  

Bora Chairman Bobby Sheng added that the acquisition is an important milestone as the company continues to expand its presence in the CDMO market. 

In December 2021 the company announced a partnership with Taishin Healthcare Limited Partnership, where the two parties would invest $108 million to expand its footprint in the CDMO sector and enter the macromolecular/cell and gene therapy manufacturing space.  

The company recently announced the establishment of Bora Biologics to focus on this expansion. Alongside Taishin, Tanvex BioPharma founder Dr. Allen Chao is an investor.  

Bora Pharmaceuticals is a CDMO specializing in a wide range of complex dosage forms including oral solid, liquid, and semi-solid capabilities for both Rx and OTC products, with facilities in Asia and North America.